A Global View: NanoLogix Creates Science Advisory Board

HUBBARD, Ohio, May 11 /PRNewswire-FirstCall/ -- NanoLogix, Inc. (Pink Sheets:
NNLX) is pleased to announce the creation of its Science Advisory Board to
help evaluate and target research and development efforts for products. The
new advisory board provides the company with a vastly expanded scope of
expertise in both medicine and biomedical research.

Dr. Robert Ollar, NanoLogix cofounder and author of numerous NanoLogix
patents, has resigned from the NanoLogix Board of Directors to assume the
position of Chairman of the Science Advisory Board.

NanoLogix Science Advisory Board Members

Dr. Robert A. Ollar, M. Sc., Ph.D.
Chairman of the Science Advisory Board. Dr. Ollar is the director of the Core
Molecular Biology Program of the Department of Surgery at St. Vincent's
Hospital in Manhattan. He is also an Assistant Professor at New York Medical
College. His background includes work in scientific research, medical
education, and biotechnology.

He brings to the Board decades of experience in the fields of medical
microbiology, mycobacteriology, medical mycology, and molecular biology. He
serves as advisor to the WHO Global Stop TB Partnership, CDC TB Training and
Educational Network, and the Mahatma Gandhi Institute for Medical Sciences in
India in the fields of TB and AIDS-related mycobacterial Diseases.

Dr. Ollar's current focus is on the development of molecular technologies for
rapid detection of pancreatic and colorectal cancers.

Sergey V. Gazenko, Ph.D., NanoLogix Vice-President of Research and
Development. Dr. Gazenko holds his doctoral degree from The Institute of
Applied Biochemistry in Moscow. Dr. Gazenko has worked for more than 28 years
in the area of microbiological diagnostics and is the author of numerous
scientific publications and patents. He is the author of both granted and
patents pending for BNP(TM) and BNC(TM) rapid test kits. His current focus is
on enhancements to both BNP and BNC technologies.

Dr. Brian Caplin, Ph.D.
Dr. Caplin holds a doctorate in the fields of biochemistry and molecular
biology. He is an internationally respected expert in the new field of Real
Time Polymerase Chain Reaction and is president of his own firm,
Fluoresentric, Inc. He brings to the advisory board an extensive insight into
the links of traditional growth-based technologies to the expanding world of
real time diagnostics and microarray-based systems for the identification of
large panels of microbial pathogens, important in areas such as medical
veterinary microbiology and biodefense.

Dr. T. Dorai, M.Sc., Ph.D.
Associate Professor and Director of Research, Department of Urology, Saint
Vincent's Hospital and New York Medical College, Manhattan. Dr. Dorai has
broad based skills in the fields of microbiology, immunology, biochemistry and
molecular biology. As a professor and researcher at numerous institutes in
India, Los Angeles and New York City, and with 47 publications to his name,
Dr. Dorai reflects a global perspective shared by other board members.

Dr. Sushil Duddempudi, MD
Assistant Professor of Medicine, Texas A&M Health Science Center, Temple,
Texas. Dr. Duddempudi is a physician and gastroenterologist with unique
insights into medical needs for specific types of diagnostic technology and
methodologies. His knowledge of gastrointestinal disease provides NanoLogix
with a specialized understanding of the unique problems associated with
gastrointestinal infections, such as salmonella, cholera, and campylobacteria.

Dr. Deepak Kumar Mendiratta, MD, Ph.D.
Dr. Mendiratta is chairman of the Department of Microbiology at the Mahatma
Gandhi Institute of Medical Sciences. He holds both scientific and medical
graduate and post-graduate credentials.

Dr. Mrs. P. Narang, MD
Dr. Narang is an internationally respected physician in the fields of
microbiology, medical education, and public health. Formerly dean of the
Mahatma Gandhi Institute of Medical Science, and chairman of its Department of
Microbiology, she has lectured worldwide on Public Health topics related to
infections disease pathogens, especially in the realm of Global TB. Dr. Narang
pioneered the field of AIDS-related non-tuberculous mycobacterial research in
India, increasing awareness throughout India of the importance of prompt
identification and treatment of these pathogens in the Indian AIDS patient
population.

Dr. Ravinder Narang, MD
An internationally respected surgeon and educator, Dr. Narang has written
extensively on infectious disease and oncology and participated in numerous
programs involving both national and international (WHO) public health
agencies. He brings to the Science Advisory Board a surgeon's unique
perspective on operative and post-operative complications related to
infectious agents.

Cliff Watts, MD
Dr. Watts has been an Emergency Room physician for almost thirty-five years.
During his tenure at Boulder Community Hospital, Dr. Watts has often been on
the front line of treating patients with life threatening diseases, and has a
practical understanding of the needs in rapid response medicine. His
contribution to the board is based upon extensive practical experience in
urgent care, public health, and time-sensitive response to treatment.

Chris Novak, NanoLogix Director of Intellectual Property. Mr. Novak is a
registered patent attorney and is licensed to practice law in several states.
Mr. Novak earned a Juris Doctor (J.D.) degree from Marquette University where
he also earned a BSME. He also holds a MSEE degree from California Polytechnic
State University, and is currently working towards a degree in biotechnical
science.

About NanoLogix, Inc.
NanoLogix is a biotechnology company focused primarily on medical diagnostics.
Its products offer accelerated detection and identification of microorganisms
present in infectious and non-infectious human diseases, such as tuberculosis,
NTM, pneumonia, HIV/AIDS, cancer, cystic fibrosis, anthrax, and plague. In
addition to medical, Defense, and homeland security applications, NanoLogix
technology is applicable in pharmaceutical, industrial, veterinary and
environmental testing.

Patents granted to NanoLogix can be used in the areas of applied microbiology,
soil microbiology and bioremediation, microbial physiology, molecular biology,
pharmacology, pharmaco-kinetics, antibiotic sensitivity, stem-cell research,
and bioreactor-based hydrogen generation.

More information on NanoLogix is available at: www.nanologix.com

This press release contains statements, which may constitute "forward- looking
statements" within the meaning of the Securities Act of 1933 and the
Securities Exchange Act of 1934, as amended by the Private Securities
Litigation Reform Act of 1995. Those statements include statements regarding
the intent, belief or current expectations of NanoLogix, Inc., and members of
its management as well as the assumptions on which such statements are based.
Prospective investors are cautioned that any such forward-looking statements
are not guarantees of future performance and involve risks and uncertainties,
and that actual results may differ materially from those contemplated by such
forward-looking statements. The Company undertakes no obligation to update or
revise forward-looking statements to reflect changed assumptions, the
occurrence of unanticipated events or changes to future operating results.

Contact:
NanoLogix, Inc.
Investor Relations
Carol Surrena
Telephone: 330-534-0800
E-mail: carol@nanologix.com

SOURCE NanoLogix, Inc.

Carol Surrena, Investor Relations of NanoLogix, Inc., +1-330-534-0800,
carol@nanologix.com